Updated Jul 16, 2026
Noci Darlene has filed 6 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $12.66M.
Darlene Noci is the Chief Development Officer at Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on targeted cancer therapies. She has been involved in multiple SEC filings related to her role in the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 14.3K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | A — Grant or award | 14.3K | $0.00 | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 41.1K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | J — Other acquisition / disposition | 17.0K | $124.00 | $2.11M |
| 2026-07-06 | NUVL | Nuvalent, Inc. | S — Open-market sale | 23.0K | $123.59 | $2.84M |
| 2026-07-06 | NUVL | Nuvalent, Inc. | M — Option exercise | 13.9K | $72.35 | $1.00M |
| 2026-07-06 | NUVL | Nuvalent, Inc. | M — Option exercise | 9.1K | $18.93 | $173K |
| 2026-07-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 5.5K | $123.51 | $679K |
| 2026-07-01 | NUVL | Nuvalent, Inc. | M — Option exercise | 5.5K | $27.85 | $153K |
| 2026-06-11 | NUVL | Nuvalent, Inc. | S — Open-market sale | 20.0K | $122.81 | $2.46M |
| 2026-06-11 | NUVL | Nuvalent, Inc. | M — Option exercise | 9.3K | $18.93 | $176K |
| 2026-06-11 | NUVL | Nuvalent, Inc. | M — Option exercise | 685 | $6.89 | $5K |
| 2026-06-11 | NUVL | Nuvalent, Inc. | M — Option exercise | 10.0K | $1.08 | $11K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 100 | $109.76 | $11K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.5K | $109.30 | $164K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.2K | $108.01 | $127K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.4K | $107.33 | $153K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.3K | $106.26 | $138K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | M — Option exercise | 5.5K | $27.85 | $153K |
| 2026-05-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 300 | $101.17 | $30K |
Darlene Noci is the Chief Development Officer at Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on targeted cancer therapies. She has been involved in multiple SEC filings related to her role in the company.…
6 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 55 open-market sales ($12.66M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Noci Darlene profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.